We are live on ! Find out more
ECM

Endurant Capital Management Portfolio holdings

AUM $17.4M
1-Year Est. Return 7.38%
This Fund
S&P 500
This Quarter Est. Return
+2.69%
1 Year Est. Return
+7.38%
3 Year Est. Return
+18.38%
5 Year Est. Return
+100.61%
10 Year Est. Return
–
AUM
$414M
AUM Growth
-$24.8M
Cap. Flow
+$88.7M
Cap. Flow %
21.41%
Top 10 Hldgs %
52.02%
Holding
86
New
35
Increased
13
Reduced
20
Closed
18

Top Buys

Rank Stock Value
1
AZN icon
AstraZeneca
AZN
+$19.1M
2
SNY icon
Sanofi
SNY
+$18.3M
3
LH icon
Labcorp
LH
+$13.4M
4
COR icon
Cencora
COR
+$11.5M
5
CRL icon
Charles River Laboratories
CRL
+$7.22M

Top Sells

Rank Stock Value
1
ABBV icon
AbbVie
ABBV
+$19.5M
2
BMY icon
Bristol-Myers Squibb
BMY
+$12.5M
3
ICLR icon
Icon
ICLR
+$12.2M
4
JNJ icon
Johnson & Johnson
JNJ
+$9.06M
5
ACH
Accendra Health
ACH
+$7.11M

Sector Composition

Rank Sector Weight
1 Healthcare 72.05%
2 Industrials 1.26%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AVTR icon
26
Avantor
AVTR
$9.14B
$4.51M 1.09%
106,996
-54,967
-34% -$2.17M
HAE icon
27
Haemonetics
HAE
$3.85B
$3.92M 0.95%
+73,914
New +$4.5M
VCYT icon
28
Veracyte
VCYT
$3.81B
$3.6M 0.87%
87,343
-80,868
-48% -$3.57M
ADAP
29
DELISTED
Adaptimmune Therapeutics
ADAP
$3.37M 0.81%
897,579
-19,909
-2% -$90.6K
SRPT icon
30
Sarepta Therapeutics
SRPT
$1.75B
$2.99M 0.72%
+33,191
New +$2.84M
KNSA icon
31
Kiniksa Pharmaceuticals
KNSA
$5.99B
$2.87M 0.69%
+244,125
New +$3M
IWM icon
32
PUT
iShares Russell 2000 ETF
IWM
$83.3B
$2.67M 0.64%
+12,000
New +$2.71M
ZGNX
33
DELISTED
Zogenix, Inc.
ZGNX
$2.61M 0.63%
+160,640
New +$2.35M
INSM icon
34
Insmed
INSM
$21.6B
$2.43M 0.59%
89,211
-70,692
-44% -$2.02M
AHCO icon
35
AdaptHealth
AHCO
$884M
$2.4M 0.58%
97,926
-96,960
-50% -$2.28M
GDRX icon
36
GoodRx Holdings
GDRX
$1.11B
$2.24M 0.54%
+68,599
New +$2.76M
FATE icon
37
Fate Therapeutics
FATE
$308M
$2.18M 0.53%
+37,325
New +$2.12M
AXSM icon
38
Axsome Therapeutics
AXSM
$11.1B
$2.1M 0.51%
55,629
+3,581
+7% +$132K
RYTM icon
39
Rhythm Pharmaceuticals
RYTM
$7.54B
$1.97M 0.48%
+197,462
New +$2.22M
ICUI icon
40
ICU Medical
ICUI
$4.22B
$1.84M 0.44%
+7,766
New +$1.81M
IMUX icon
41
Immunic
IMUX
$193M
$1.77M 0.43%
18,454
-91
-0.5% -$8.2K
PRAX icon
42
Praxis Precision Medicines
PRAX
$8.84B
$1.76M 0.43%
5,971
-4,269
-42% -$1.25M
PODD icon
43
Insulet
PODD
$9.33B
$1.7M 0.41%
+6,394
New +$1.85M
ATRC icon
44
AtriCure
ATRC
$1.94B
$1.69M 0.41%
+24,253
New +$1.76M
STRO icon
45
Sutro Biopharma
STRO
$431M
$1.66M 0.4%
+11,180
New +$2M
AUPH icon
46
Aurinia Pharmaceuticals
AUPH
$1.95B
$1.53M 0.37%
+66,935
New +$1.59M
ALBO
47
DELISTED
Albireo Pharma Inc
ALBO
$1.53M 0.37%
65,638
-51,690
-44% -$1.37M
HRTX icon
48
Heron Therapeutics
HRTX
$96.6M
$1.51M 0.36%
+165,404
New +$1.69M
VRDN icon
49
Viridian Therapeutics
VRDN
$2.33B
$1.33M 0.32%
+67,450
New +$1.26M
GOSS icon
50
Gossamer Bio
GOSS
$87.5M
$1.28M 0.31%
+113,660
New +$1.35M
1
2
3 4

Similar funds

VAFP
Vahanian & Associates Financial Planning Saratoga Springs, New York $25.3M AUM 39.42% 1-Year Est. Return
CA
Corriente Advisors Fort Worth, Texas $9.53M AUM 805.26% 1-Year Est. Return
SCM
Somerset Capital Management London, United Kingdom $8.12M AUM 21.3% 1-Year Est. Return
FWM
Fiat Wealth Management Wayzata, Minnesota $7.9M AUM
TOPU
Trustees of Princeton University Princeton, New Jersey $7.77M AUM
CCMU
Cheyne Capital Management (UK) London, United Kingdom $27.9M AUM 36.14% 1-Year Est. Return
TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
HSCU
Half Sky Capital (UK) London, United Kingdom $30.5M AUM 67.32% 1-Year Est. Return

Endurant Capital Management's Q4 2021 Portfolio in Review

As of Q4 2021, Endurant Capital Management held 86 positions worth $414M, down 5.7% from $439M the previous quarter. Its ten largest holdings account for 52% of the portfolio.

Endurant Capital Management deployed $88.7M of net new capital in Q4 2021, opening 35 new positions and adding to 13 existing holdings. Its largest new stake was AstraZeneca: 162,364 shares worth $18.9M.

By sector, the portfolio is most concentrated in Healthcare at 72% of assets, up from 60% a quarter earlier, followed by Industrials.

On the sell side, the largest reduction was Johnson & Johnson, an estimated $9.06M trimmed.

  • Endurant Capital Management's largest Q4 2021 buy was AstraZeneca: 162,364 shares worth $18.9M.
  • Endurant Capital Management added most to Sanofi in Q4 2021, an estimated $18.3M increase.
  • Endurant Capital Management's biggest Q4 2021 reduction was Johnson & Johnson, cutting an estimated $9.06M.
  • Endurant Capital Management fully exited AbbVie in Q4 2021, selling an estimated $19.5M.
  • Endurant Capital Management's ten largest holdings make up 52% of its $414M portfolio in Q4 2021.
  • Endurant Capital Management opened 35 new positions and closed 18 in Q4 2021.
  • Endurant Capital Management's portfolio value fell 5.7% quarter-over-quarter to $414M.

Based on Endurant Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.